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Skeletal muscle cells have served as a paradigm for understanding
mechanisms leading to cellular differentiation. The proliferation
and differentiation of muscle precursor cells require the concerted
activity of myogenic regulatory factors including MyoD. In addi-
tion, chromatin modiﬁers mediate dynamic modiﬁcations of
histone tails that are vital to reprogramming cells toward terminal
differentiation. Here, we provide evidence for a unique dimension
to epigenetic regulation of skeletal myogenesis. We demonstrate
that the lysine methyltransferase G9a is dynamically expressed
in myoblasts and impedes differentiation in a methyltransferase
activity-dependent manner. In addition to mediating histone H3
lysine-9 di-methylation (H3K9me2) on MyoD target promoters, en-
dogenous G9a interacts with MyoD in precursor cells and directly
methylates it at lysine 104 (K104) to constrain its transcriptional
activity. Mutation of K104 renders MyoD refractory to inhibition
by G9a and enhances its myogenic activity. Interestingly, MyoD
methylation is critical for G9a-mediated inhibition of myogenesis.
These ﬁndings provide evidence of an unanticipated role for meth-
yltransferases in cellular differentiation states by direct posttrans-
lational modiﬁcation of a transcription factor.
Skeletal muscle differentiation is controlled by theMyoD familyof myogenic regulatory factors and chromatin modifying
enzymes that reconﬁgure chromatin at muscle-speciﬁc promoters
(1–6). Epigenetic modiﬁcations constitute a complex regulatory
layer to restrict or facilitate gene expression. In undifferentiated
cells, marks of transcriptional repression including H3K9 and
H3K27 methylation are apparent on early and late muscle gene
promoters, along with reduced acetylation of histone tails. Many
enzymes that regulate these histone modiﬁcations have been stud-
ied, including histone deacetylases (HDACs) and histone methyl-
transferases (HMTs). Protein complexes of the polycomb (PcG)
group catalyze trimethylation of H3K27 (H3K27me3), and HMTs
from the Suv39h family mediate H3K9 methylation (7–12). The
onset of differentiation requires extensive reprogamming at muscle
promoters. Several coactivator proteins including CBP/p300, P/
CAF, the argininemethyltransferases Carm1/Prmt4 and Prmt5, and
the SWI/SNF remodeling complexes are recruited, which substitute
the repressive chromatin conﬁguration in undifferentiated cells
with transcriptional activation marks. Despite extensive inves-
tigations, however, it remains unclear how MyoD, which is
expressed in undifferentiated proliferating myoblasts, remains
transcriptionally inert and unable to activate muscle-speciﬁc genes
until appropriate differentiation cues are established (13–16).
A key modiﬁcation that is apparent on the early MyoD target
gene myogenin in undifferentiated muscle cells is H3K9me2 (9,
10). This transcriptional repressive mark is mediated mostly by
the SET domain containing Suv39 family members that include
EHMT2/G9a and Suv39h1 (17). Although both G9a and
Suv39h1 mediate H3K9 methylation, their activities are distinct.
G9a is mainly responsible for mono- and dimethylation of H3K9
(H3K9me1 and H3K9me2, respectively), which is scattered in
euchromatin, whereas Suv39h1, the principal enzyme responsible
for accumulation of H3K9me3, is enriched in heterochromatin.
More recent studies have demonstrated that in addition to me-
diating H3K9me2, G9a can methylate nonhistone substrates,
including CDYL1, WIZ, ACINUS, and C/EBPβ (18), and also
associates with de novo DNA methyltransferases 3a and 3b to
repress transcription (19). Loss of G9a in mice leads to early
embryonic lethality, which has precluded the understanding of its
function in speciﬁc cellular differentiation pathways (20).
In this study, we demonstrate that G9a is a unique inhibitor of
skeletal muscle differentiation that plays a dominant role in
MyoD activation. G9a-mediated inhibition of the muscle differ-
entiation program depends on its methyltransferase activity, be-
cause pharmacological blockage of G9a activity, or expression of
a catalytically inactive mutant, fail to impact myogenesis. In-
terestingly, G9a interacts with MyoD in undifferentiated cells,
and methylates it at K104, which inhibits its activity. Mutation of
K104 renders MyoD refractory to inhibition by G9a and enhan-
ces its myogenic potential. Our data identify MyoD methylation
as a distinct epigenetic modiﬁcation that plays a prominent role
in restricting MyoD activity in myoblasts and, consequently,
skeletal muscle differentiation.
Results
G9a Inhibits Skeletal Muscle Differentiation in a Methyltransferase
Activity-Dependent Manner. To examine whether G9a plays a role
in skeletal myogenesis, we ﬁrst investigated its expression in
undifferentiated and differentiated cells. G9a mRNA was
expressed at high levels in C2C12 cells and in undifferentiated
primary myoblasts, and it was down-regulated during differen-
tiation (Fig. 1 A and B). Consistently, G9a protein levels also
declined upon differentiation and inversely correlated with the
expression of MyoD target genes myogenin and troponin T (Fig.
1C). G9a was expressed in the nucleus in undifferentiated
myoblasts and remained nuclear, albeit at much lower expres-
sion, in MHC+ differentiated cells (Fig. S1). To investigate
whether G9a regulates myogenic differentiation, we performed
gain-of-function studies. C2C12 cells expressing full-length G9a
(EGFP-G9a), or a deletion mutant lacking the SET domain
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(EGFP-G9aΔSET), were analyzed for their ability to differenti-
ate relative to control vector (EGFP) expressing cells. Both
EGFP-G9a and EGFP-G9aΔSET were expressed at similar
levels (Fig. 1D). In contrast to control and EGFP-G9aΔSET
cells, EGFP-G9a cells exhibited a signiﬁcant reduction in dif-
ferentiation as evidenced by reduced myogenic index (Fig. 1 E
and F). Moreover, myogenin and troponin T levels were reduced
in EGFP-G9a cells (Fig. 1G), indicating that G9a-mediated in-
hibition of myogenesis depends on its methyltransferase activity.
To conﬁrm these ﬁndings, BIX-01294, a inhibitor of G9a activity
(21) was used. G9a-overexpressing cells were left untreated, or
treated with BIX-01294 for 3 d, and the extent of differentiation
examined. Inhibition of G9a activity in EGFP-G9a–over-
expressing cells led to a signiﬁcant rescue of myogenic differ-
entiation (Fig. 1H) and troponin T expression (Fig. 1I).
To conﬁrm that endogenous G9a plays a role in myogenic
differentiation, we used two approaches. In one, G9a expression
was inhibited with siRNA, and in the other, its activity was tar-
geted by using BIX-01294. C2C12 cells were transfected with
G9siRNA (siG9a), or as a control, with scrambled siRNA
(siRNA). Densitometric analysis of Western blots revealed
a 71% down-regulation of G9a expression in siG9a cells com-
pared with untransfected cells, or those expressing siRNA (Fig.
2A). Compared with controls, siG9a cells exhibited markedly
higher myogenic differentiation (Fig. 2 B and C), and an earlier
onset of myogenin and troponin T expression (Fig. 2D). More-
over, myogenin mRNA was up-regulated in siG9a cells cultured
in growth and differentiation medium (Fig. 2E). Consistently,
inhibition of endogenous G9a activity in control C2C12 cells
resulted in a signiﬁcant increase in myogenic differentiation (Fig.
2 F and G), as well as myogenin and troponin T levels (Fig. 2H).
G9a Interacts with and Inhibits MyoD Activity. Because G9a is
expressed in myoblasts and inhibits genes that are induced dur-
ing differentiation, we tested whether it regulates myogenic
regulatory factor (MRF) activity. C2C12 myoblasts were trans-
fected with the MRF reporter 4RTK-Luc in the absence and
presence of EGFP-G9a or EGFP-G9aΔSET. Interestingly,
EGFP-G9a potently repressed the reporter activity in a SET-
domain–dependent manner (Fig. 3A), suggesting that G9a may
inhibit endogenous MyoD and/or Myf5 transcriptional activity.
To examine the effect of G9a speciﬁcally on MyoD activity,
C3H10T1/2 ﬁbroblast cells were used that do not express en-
dogenous MyoD, but readily undergo myogenic conversion upon
exogenous MyoD expression. Cells were transfected with 4RTK-
Luc and MyoD in the absence and presence of EGFP-G9a and
EGFP-G9aΔSET. MyoD activated the reporter, whereas coex-
pression of EGFP-G9a, but not EGFP-G9aΔSET, blocked this
effect (Fig. 3B). Similarly, MyoD-mediated activation of the
myogenin promoter reporter (22) was inhibited by G9a (Fig. 3C).
Consistent with these ﬁndings, MyoD-induced reporter activity
was augmented in the presence of BIX-01294 (Fig. 3D). To in-
vestigate the mechanisms underlying the inhibition of its activity,
we tested whether G9a associates with MyoD. Immunoprecipi-
tation of either G9a or MyoD revealed an interaction between
the two proteins (Fig. 3E), and colocalization of endogenous G9a
and MyoD was apparent in undifferentiated cells (Fig. S2). To
examine the impact of G9a on MyoD function, myogenic con-
version assays were performed. 10T1/2 cells were transfected
with MyoD alone, or together with equivalent amounts of EGFP-
G9a and EGFP-G9aΔSET (Fig. 3F). EGFP-G9a, but not EGFP-
G9aΔSET, inhibited MyoD-dependent myogenic conversion as
seen by a signiﬁcant reduction in the presence of myosin heavy
Fig. 1. G9a inhibits differentiation in a methyltransferase activity-dependent manner. (A and B) G9a mRNA was examined in undifferentiated (Day 0) and
differentiated (Days 1 and 3) in C2C12 cells (A), as well as primary myoblasts (B) by Q-PCR. (C) G9a, myogenin, and troponin T protein levels were analyzed in
C2C12 cells by Western blot. (D) C2C12 overexpressing EGFP-G9a, EGFP-G9aΔSET, or EGFP (vector) were analyzed for G9a expression by Western blot. (E)
Control and EGFP-G9a or EGFP-G9aΔSET expressing cells were immunostained with α-MHC antibody. (F) A signiﬁcant decrease in myogenic index was ap-
parent in EGFP-G9a cells compared with control and EGFP-G9aΔSET cells. (G) Control, EGFP-G9a, and EGFP-G9aΔSET cells were analyzed for myogenin and
troponin T expression by Western blot. (H and I) EGFP-G9a–overexpressing cells were left untreated or treated with BIX-01294 for 3 d. A signiﬁcant rescue of
the myogenic index (H) and troponin T levels (I) was apparent upon inhibition of G9a activity. Error bars indicate mean ± SD. **P < 0.01; ***P < 0.001.
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chain (MHC+) myotubes (Fig. 3G), myogenic index (Fig. 3H),
and troponin T expression (Fig. 3I).
MyoD Is Methylated by G9a.Toexamine themechanisms underlying
inhibition of MyoD activity, we ﬁrst examined by chromatin im-
munoprecipitation (ChIP) assays enrichment of H3K9me2, a
transcriptional repression mark mediated by G9a. Consistent with
previous reports (9), H3K9me2 was apparent on the myogenin
promoter in undifferentiated EGFP-expressing C2C12 cells and
declined upon differentiation. In G9a-overexpressing cells, in-
creased H3K9me2 was apparent in both undifferentiated and dif-
ferentiated cells (Fig. 4A). BecauseG9a complexes withMyoDand
is known to methylate nonhistone proteins, we wondered whether
MyoD could be a target for G9a-mediatedmethylation. Analysis of
the human and mouse MyoD cDNA sequence revealed a single
G9a-methylation consensus RK at K104 (Fig. 4B). To test this
possibility, MyoD was coexpressed with EGFP-G9a, or EGFP-
G9aΔSET, and its methylation was examined after immunopre-
cipitation. Both EGFP-G9a and EGFP-G9aΔSET interacted with
MyoD. However, MyoD was methylated only in presence of
EGFP-G9a (Fig. 4C). Consistently, endogenous MyoD immuno-
precipitated with G9a in myoblasts and was methylated (Fig. 4D).
To examine whether G9a is involved in MyoD methylation, we
modulated its levels and examined the impact on MyoD methyla-
tion. Overexpression of G9a resulted in enhanced MyoD methyl-
ation (Fig. 4E) and, conversely, abrogated it in siG9a cells (Fig. 4F).
Inhibition of endogenous G9a activity resulted in reduced MyoD
methylation in both undifferentiated and differentiated cells (Fig.
4G).Moreover, deletion of the ankyrin repeats inG9a (G9aΔANK)
disrupted the association with MyoD and, correspondingly, its
methylation, indicating that interaction with G9a is required for
MyoD methylation (Fig. S3A).
We then examined whether G9a directly methylates MyoD
in vitro by using GST-MyoD. GST-histone H3 (GST-H3) was
used as a control. G9a methylated MyoD, albeit at a lower ef-
ﬁciency compared with H3 (Fig. 4H), whereas no methylation
was apparent with the SET mutant (hG9aΔSET). In addition,
SET7/9 also weakly methylated MyoD, suggesting that additional
methyltransferases may also modify MyoD. Liquid chromatog-
raphy-mass spectrometry (LC-MS) of the recombinant MyoD
polypeptide treated with wild-type or mutant (ΔSET) G9a
identiﬁed K104 as the site for methylation (Fig. 4I), consistent
with a G9a-methylation consensus at this residue (Fig. 4B). To
validate these ﬁndings, we transfected 293 cells with wild-type
MyoD and MyoD(RRR), in which K99, K102, and K104 are
mutated to arginine (RRR) (14) along with EGFP-G9a. MyoD
was immunoprecipitated and probed for methylation by using
methyl-lysine antibody. In contrast to MyoD, MyoD(RRR) was
not methylated in presence of G9a (Fig. 4J).
To address the signiﬁcance of H3K9me2 versus MyoD meth-
ylation in G9a-mediated inhibition of myogenesis, we examined
the ability of MyoD and MyoD(K104R) (where K104 is mutated
to arginine; ref. 14) to rescue the differentiation block imposed
by G9a. In G9a-overexpressing cells (Fig. 4K, Upper Left),
equivalent levels of each MyoD construct was expressed (Fig. 4K,
Upper Right). Interestingly, MyoD(K104R) was more efﬁcient
than MyoD at rescuing myogenic differentiation (Fig. S3 B and
C) and troponin T levels (Fig. 4K, Lower), likely due to its in-
ability to be methylated by G9a. To validate these ﬁndings, we
examined the myogenic potential of MyoD and MyoD(K104R)
Fig. 2. Myogenic differentiation is enhanced by loss of G9a. (A) C2C12 cells were transfected with G9a siRNA (siG9a), scrambled siRNA (siRNA), or left
untransfected (control). Lysates were analyzed for endogenous G9a protein levels by Western blot. (B) Cells were subjected to differentiation assays and
stained with α-MHC antibody (green) on Day 2 after differentiation. Nuclei were stained with DAPI. (C) Quantiﬁcation of myogenic index on Day 2 after
differentiation revealed signiﬁcantly enhanced MHC+ cells in siG9a cells. (D) Myogenin and troponin T expression was determined by Western blot at Days 0,
1, and 2 after differentiation. (E) Myogenin mRNA levels were measured in control and siG9a cells at D0 and D2 after differentiation by Q-PCR. Error bars
indicate mean ± SD. (F and G) Endogenous G9a activity was blocked in C2C12 cells with BIX-01294. MHC+ cells (F) and myogenic index (G) were determined in
cells left untreated (-), or after treatment (+) with BIX-01294 for 2 d. (H) Myogenin and troponin T expression was increased in cells treated with BIX-01294
compared with control untreated cells. *P < 0.05; **P < 0.01; ***P < 0.001.














in myogenic conversion assays (Fig. 4L, Upper). As expected,
expression of MyoD alone resulted in troponin T expression and
myogenic differentiation, which was augmented by BIX-01294
(Fig. 4L, Lower and Fig. S3D). In contrast, expression of MyoD
(K104R) at similar levels resulted in higher troponin T expres-
sion and myogenic differentiation, which, however, was un-
responsive to G9a inhibition by BIX-01294. Consistently, MyoD
(K104R) showed increased transactivation of the myogenin
promoter (Fig. S3E), although the levels of H3K9me2 were
unaltered in the presence of MyoD and MyoDK104R (Fig. S3F).
Together, these results support a dominant role for MyoD K104
methylation in the inhibition of differentiation by G9a.
Discussion
The transition of cells from an undifferentiated to a differenti-
ated state provide a powerful system for investigating epigenetic
mechanisms that inﬂuence cellular fate. The results of this study
demonstrate an unconventional epigenetic mechanism that
connects the lysine methyltransferase G9a to maintenance of an
undifferentiated fate by methylation of MyoD.
In agreement with an inhibitory role in skeletal muscle dif-
ferentiaton, G9a is expressed at high levels in proliferating
myoblasts and inversely correlated with MyoD transcriptional
activity and the onset of myogenin expression during differenti-
ation. Similar to G9a, other chromatin modifers are expressed in
undifferentiated myoblasts including HDAC1 (7, 8) and Suv39h1,
both of which interact with MyoD (12, 23). However, unlike these
enzymes, which act locally to deacetylate and methylate histones
resulting in chromatin conﬁgurations that are nonpermissive for
MyoD transcriptional activity, G9a not only mediates H3K9me2,
but also directly methylates MyoD at K104. Although G9a is
known to mediate methylation of both histone and nonhistone
substrates, the biological functions of nonhistone methylations
are largely unclear. In this regard, our data provide unique
insights into the function of methylation of a nonhistone substrate
in the control of cellular differentiaion. Our data indicate that
MyoD methylation, rather than alterations in H3K9me2, are sig-
niﬁcant in G9a-mediated inhibition of myogenesis. This inference
is based on the strikingly differential abilities of wild-type MyoD
and MyoD(K104R) in rescuing myogenic differentiation in G9a-
overexpressing cells that have similar levels of H3K9me2. MyoD
(K104R) exhibits higher myogenic potential in myogenic conver-
sion assays, and in activation of the myogenin promoter, while
being unresponsive to G9a. Based on the crystal structure of
MyoD–DNA complex, K104 does not make contact with DNA
and, correspondingly, its mutation does not impact MyoD DNA
binding or nuclear localization (14, 24). Therefore, our data col-
lectively argue that MyoD methylation is critical in regulation of
its transcriptional activity, and the onset of MyoD-dependent gene
expression during differentiation. Although methylation of MyoD
has not been described in the literature, it is noteworthy that
in vitro, MyoD is methylated not only by G9a, but also by Set7/9.
It is unlikely that methylation of MyoD by G9a and Set7/9 occur
on the same residue because they have distinct substrate
requirements (25). MyoD is constitutively bound to several pro-
moters in both myoblasts and myotubes. It is unclear whether G9a
activity has a role in regulating MyoD-activated target genes in
myoblasts. Nevertheless, G9a blocks the differentiation-inducing
ability of MyoD through methylation of K104 in euchromatin of
myoblasts. In addition to G9a, several other chromatin modiﬁer
complexes containing Suv39h1, HP1, HDAC1, and Ezh2 con-
tribute toward the generation of a stable H3K9me3, H3K27me3,
Fig. 3. G9a inhibits MyoD activity. (A) C2C12 cells were transfected with 4RTK-Luc (50 ng) in the absence and presence (50, 25, and 10 ng) of EGFP-G9a or
EGFP-G9aΔSET. Data are means ± SD. (B and C) 10T1/2 cells were transfected with 4RTK-Luc and MyoD along with EGFP-G9a, and EGFP-G9aΔSET (B), or with
pMyogLuc (80 ng) and MyoD (50 ng), without and with Flag-G9a (50 ng) (C). (D) 10T1/2 cells were transfected with 4RTK-Luc and MyoD in the absence and
presence of BIX-01294. (E) 293 cells were transfected with Flag-G9a and Myc-MyoD. Proteins were immunoprecipitated with α-Flag or α-Myc agarose beads
and immunoblotted with α-Myc or α-Flag antibody, respectively. Lysates (input) were analyzed for G9a, and MyoD expression was analyzed by Western blot.
(F–I) 10T1/2 cells were transfected with MyoD, EGFP-G9a and EGFP-G9aΔSET and analyzed by Western blot (F). Transfected cells were subjected to myogenic
conversion assays. Cells were stained with α-MHC (green) antibody (G). The percentage of MHC+ cells was quantiﬁed relative to MyoD alone, which was given
a value of 100%. A signiﬁcant decrease in myogenic index was apparent in cells overexpressing EGFP-G9a and MyoD (H). Troponin T levels analyzed by
Western blot were reduced in cells coexpressing MyoD and G9a compared with controls (I). Data are mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001.
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and deacetylated state, resulting in silencing of early and late
myogenic promoters (11, 12, 23). During differentiation, the de-
clining G9a levels would expectedly erase MyoD methylation.
Moreover, Suv39h1, HDAC1, and Ezh2 also are down-regulated
at the onset of differentiation. Thus, H3K9me2, H3K27me3, and
histone deacetylation marks on MyoD target promoters are re-
moved, paving the way for MyoD and histone activation that are
permissive for myogenic differentiation.
Materials and Methods
Cell Culture and Plasmid Constructs. C2C12, 293, C3H10T1/2, primarymyoblasts,
and Phoenix cells were cultured as described (26, 27). Plasmids Myc-MyoD,
Flag-MyoD, Flag-MyoD(K104R), Flag-MyoD(RRR), 4RTK-Luc, pMyogLuc re-
porter harboring 1565 base pairs of upstream sequences from the myogenin
gene, Flag-G9a, EGFP-G9a, and EGFP-G9aΔSET have been described (14, 22,
26–28). Primers used to generate Flag-G9aΔANK are provided in Table S1.
G9a Overexpression, siRNA, and Myogenic Differentiation. For G9a over-
expression, EGFP-G9a, EGFP-G9aΔSET, or Flag-G9a were transfected in C2C12
cells along with pBabe-puromycin. Cells were selected with 2 μg/mL puro-
mycin (26) and differentiated in the absence or presence of 2.5 μM BIX-
01294. For rescue experiments, Flag-G9a–expressing cells were transfected
with MyoD or MyoD(K104R). For G9a knockdown, C2C12 cells were trans-
fected with 100 nM control scrambled siRNA (Dharmacon; on-target plus
control pool; nontargeting pool) or siRNA speciﬁc for G9a (Dharmacon; on-
Fig. 4. G9a-mediated methylation of MyoD at K104 impairs its myogenic activity. (A) ChIP assays were performed at Day 0 and Day 2 on the myogenin
promoter. Increased H3K9me2 was apparent in EGFP-G9a cells at both stages. Error bars indicate mean ± SD. (B) Schematic representation of human (h)/
mouse(m) MyoD cDNA sequence. A G9a methylation consensus (RK) at K104 is highlighted. (C) 293 cells were transfected with EGFP-G9a, EGFP-G9aΔSET, and
Myc-MyoD. MyoD was immunoprecipitated and analyzed for its association with G9a, and methylation, using α-GFP and α-methyl lysine (Me Lys) antibodies.
(D) Endogenous MyoD was immunoprecipitated from C2C12 cells on Day 0 and 2 after differentiation, followed by immunoblotting with α-G9a, α-Me Lys, and
α-MyoD antibodies. Input shows expression of G9a and MyoD in the lysates. (E). C2C12 cells were transfected with EGFP and EGFP-G9a. Endogenous MyoD
was immunoprecipitated from myoblasts and analyzed by α-Me Lys and α-MyoD antibodies. Input shows G9a and MyoD expression. (F) Endogenous MyoD
was immunoprecipitated from myoblasts expressing siG9a and control siRNA, and analyzed with α-Me Lys and α-MyoD antibodies. Lysates were analyzed for
MyoD and G9a expression. (G) C2C12 cells were differentiated in the absence and presence of BIX-01294 for 2 d. Endogenous MyoD was immunoprecipitated
followed by Western blotting with α-Me Lys antibody. (H) In vitro methylation of recombinant GST-tagged human MyoD by G9a and Set7/9 using puriﬁed
recombinant G9a, G9aΔSET, and Set7/9. GST-H3 was used as a positive control. (I) LC-MS of tryptic peptides of MyoD after treatment with the catalytically
active and inactive recombinant G9a methyltransferase. (J) Flag-MyoD and Flag-MyoD(RRR) were transfected with EGFP-G9a in 293 cells. Flag-MyoD was
immunoprecipitated, and immunoblotted with α-Me Lys and α-Flag antibodies. Lysates were analyzed for G9a and MyoD levels. (K) Flag-G9a–overexpressing
cells (Left) were transfected with MyoD and MyoD(K104R). Vector transfected cells were used as control (Right). Troponin T levels were analyzed at 0 and 3 d
after differentiation (Lower). (L) C3H10T1/2 cells were transfected with MyoD and MyoD(K104R) (Upper) and differentiated in the absence and presence
of BIX-01294. Troponin T was analyzed at 0 and 4 d after differentiation (Lower). *P < 0.05.














target plus smart pool,Mouse BAT8; accessionno. NM_147151;NM_145830) by
using Lipofectamine RNAiMAX (Invitrogen). Myogenic conversion assays were
done as described (27). Brieﬂy, C3H10T1/2 cells were transfected with MyoD
alone, or togetherwith EGFP-G9a and EGFP-G9aΔSET. For rescue experiements,
MyoD and MyoD(K104R) were transfected and differentiated in the absence
and presence of 2.5 μM BIX-01294. Parental cells were transfected with empty
vector. Differentiated cells were stained with α-MHC antibody (Sigma) and
detected with Alexa Fluor-coupled secondary antibodies. Nuclei were stained
with DAPI (Vector Laboratories) and visualized by ﬂuorescence microscopy
(Nikon Eclipse TE 2000-U) with 10× or 20× objective lens and MetaMorph
software version 7.0r3. The percentage of MHC+ cells in controls were given
a value of 100%. Myogenic index was calculated by quantifying the ratio of
nuclei in MHC+ myotubes/total nuclei. At least 600 nuclei were counted.
Coimmunoprecipitation (Co-IP) Assays and Western Blots. Co-IP assays were
done as described (26). To detect endogenous interactions, 1mg of C2C12 lysate
was incubatedwith 2μgofα-MyoDantibody. As a control, 2 μgof rabbit IgGwas
added to D0 lysate. The following antibodies were used in this study for
Western blots: α-Flag, α-Myc, α-troponin T (Sigma); α-MyoD, α-GFP, α-myogenin
(Santa Cruz Biotechnology); α-G9a (Cell Signaling, Upstate Biotechnology); and
Me Lys (Abcam). α−β-actin or α-EF-1α was used for normalization.
Chromatin Immunoprecipitation (ChIP). Assays were performed in C2C12 cells
by using the ChIP assay kit (Upstate Biotechnology) as described (29) using 2
μg of H3K9me2 (Upstate Biotechnology) antibody. Primers for ampliﬁcation
of Myogenin and β-actin promoters are provided in Table S1.
Quantitative RT-PCR (Q-PCR). Q-PCR was done as described (26). The cDNA
was ampliﬁed with primers speciﬁc to G9a, myogenin, and GAPDH
(Table S1).
In Vitro Methylation. In vitro methylation reactions were conducted as de-
scribed (28) by using 3 μg of puriﬁed poly-histidine–tagged recombinant
proteins Set7/9 or G9a in a reaction buffer containing 50 mM Tris·HCl at pH
8.5, 5 mM MgCl2, 1 mM DTT, 1 μM [14C]-labeled S-adenosyl-L-methionine
[14C]SAM (Perkin-Elmer), 50 mM SAM (Sigma), and 2 μg of GST-MyoD (43-
224) or GST-histone H3 tail (1-57). Proteins were separated on a 15% SDS-
polyacrylamide gel. Gels were visualized by Coomassie blue staining and
ﬂuorography. In parallel, the recombinant MyoD polypeptide, treated with
wild-type or mutant (ΔSET) G9a, was digested with trypsin and analyzed by
LC-MS analysis (Thermo Electron; Finnigan LTQ).
Statistical Analysis. Values are reported as mean ± SD or SE. Statistical sig-
niﬁcance was determined by the Student t test, and P values of <0.05
were considered to be statistically signiﬁcant (*P < 0.05; **P < 0.01;
***P < 0.001).
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